Sarepta Therapeutics (SRPT) Moves Higher as Ex-FDA Official Sees Accelerated Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's
March 25, 2013 2:51 PM EDTSarepta Therapeutics (Nasdaq: SRPT) is comfortably in positive territory Monday following positive commentary in Barron's over the weekend.
Traders and investors are watching Sarepta as the FDA nears a decision on its Duchenne muscular dystrophy (DMD) drug, eteplirsen. Shares of Sarepta have traded strong since positive results from a Phase 2B trial on DMD were released last October.
... More
Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's
March 25, 2013 2:51 PM EDTSarepta Therapeutics (Nasdaq: SRPT) is comfortably in positive territory Monday following positive commentary in Barron's over the weekend.
Traders and investors are watching Sarepta as the FDA nears a decision on its Duchenne muscular dystrophy (DMD) drug, eteplirsen. Shares of Sarepta have traded strong since positive results from a Phase 2B trial on DMD were released last October.
... More
